These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28712561)

  • 1. Head to head comparison of intact and C-terminal fibroblast growth factor 23 in heart failure patients with reduced ejection fraction.
    Gruson D; Ferracin B; Ahn SA; Rousseau MF
    Int J Cardiol; 2017 Dec; 248():270-273. PubMed ID: 28712561
    [No Abstract]   [Full Text] [Related]  

  • 2. Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA.
    Almahmoud MF; Soliman EZ; Bertoni AG; Kestenbaum B; Katz R; Lima JAC; Ouyang P; Miller PE; Michos ED; Herrington DM
    J Am Heart Assoc; 2018 Sep; 7(18):e008334. PubMed ID: 30371180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction.
    Koller L; Kleber ME; Brandenburg VM; Goliasch G; Richter B; Sulzgruber P; Scharnagl H; Silbernagel G; Grammer TB; Delgado G; Tomaschitz A; Pilz S; Berger R; Mörtl D; Hülsmann M; Pacher R; März W; Niessner A
    Circ Heart Fail; 2015 Nov; 8(6):1059-67. PubMed ID: 26273098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incremental value of intact fibroblast growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patients.
    Gruson D; Carbone V; Feracin B; Ahn SA; Rousseau MF
    Clin Biochem; 2018 Nov; 61():47-49. PubMed ID: 30205090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients.
    Gruson D; Ferracin B; Ahn SA; Rousseau MF
    Int J Cardiol; 2015 Jun; 189():185-7. PubMed ID: 25897901
    [No Abstract]   [Full Text] [Related]  

  • 6. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction.
    Gruson D; Lepoutre T; Ahn SA; Rousseau MF
    Int J Cardiol; 2014; 172(1):e250-2. PubMed ID: 24467978
    [No Abstract]   [Full Text] [Related]  

  • 8. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
    Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure.
    Ter Maaten JM; Voors AA; Damman K; van der Meer P; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Metra M; Navis G; Ng L; Ouwerkerk W; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zannad F; Zwinderman AH; de Borst MH
    Int J Cardiol; 2018 Feb; 253():84-90. PubMed ID: 29306478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction.
    Barroso MC; Kramer F; Greene SJ; Scheyer D; Köhler T; Karoff M; Seyfarth M; Gheorghiade M; Dinh W
    BMC Cardiovasc Disord; 2016 Oct; 16(1):199. PubMed ID: 27769173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
    Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
    Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction.
    Lok DJ; Klip IT; Voors AA; Lok SI; Bruggink-André de la Porte PW; Hillege HL; Jaarsma T; van Veldhuisen DJ; van der Meer P
    Eur J Heart Fail; 2014 Sep; 16(9):958-66. PubMed ID: 25082741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation.
    Refsgaard Holm M; Christensen H; Rasmussen J; Johansen ML; Schou M; Faber J; Kistorp C
    ESC Heart Fail; 2019 Oct; 6(5):983-991. PubMed ID: 31429530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP.
    Bayes-Genis A; Barallat J; Galán A; de Antonio M; Domingo M; Zamora E; Gastelurrutia P; Vila J; Peñafiel J; Gálvez-Montón C; Lupón J
    Rev Esp Cardiol (Engl Ed); 2015 Dec; 68(12):1075-84. PubMed ID: 26297179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study.
    Carlsen CM; Bay M; Kirk V; Gøtze JP; Køber L; Nielsen OW
    Eur J Heart Fail; 2012 Mar; 14(3):240-7. PubMed ID: 22315457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of diabetes on the predictive value of heart failure biomarkers.
    Alonso N; Lupón J; Barallat J; de Antonio M; Domingo M; Zamora E; Moliner P; Galán A; Santesmases J; Pastor C; Mauricio D; Bayes-Genis A
    Cardiovasc Diabetol; 2016 Nov; 15(1):151. PubMed ID: 27809845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
    J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction.
    Boulogne M; Sadoune M; Launay JM; Baudet M; Cohen-Solal A; Logeart D
    Int J Cardiol; 2017 Jan; 226():53-59. PubMed ID: 27788390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HE4 Serum Levels Are Associated with Heart Failure Severity in Patients With Chronic Heart Failure.
    Piek A; Meijers WC; Schroten NF; Gansevoort RT; de Boer RA; Silljé HH
    J Card Fail; 2017 Jan; 23(1):12-19. PubMed ID: 27224553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.